Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 27;25(1):262.
doi: 10.1186/s13054-021-03696-1.

What every intensivist should know about Tocilizumab

Daniel Andrea Hofmaenner  1 , Pedro David Wendel Garcia  1 , Christoph Camille Ganter  1 , Silvio D Brugger  2 , Philipp Karl Buehler  1 , Sascha David  3
Affiliations

What every intensivist should know about Tocilizumab

Daniel Andrea Hofmaenner et al. Crit Care. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

All authors confirm that they have no competing conflict of interest.

Figures

Fig. 1
Fig. 1
Longitudinal course over 20 days after Tocilizumab administration in 16 critically ill COVID-19 patients (local ethical approval: 2020-00646). Box and whiskers blots together with colored area demonstrate circulating levels of a Interleukin (IL)-6, b C-reactive protein (CRP), c procalcitonin (PCT) and d leucocytes. Days 0 = Tocilizumab administration (8 mg/kg bodyweight, max: 800 mg)
See this image and copyright information in PMC

References

    1. Paladugu S, Donato AA. Remdesivir improved time to recovery in adults hospitalized with COVID-19 and lower respiratory tract involvement. Ann Intern Med. 2020;173(2):JC4. doi: 10.7326/ACPJ202007210-005. - DOI - PubMed
    1. RECOVERY Collaborative Group. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704. doi: 10.1056/NEJMoa2021436. - DOI - PMC - PubMed
    1. REMAP-CAP Investigators. Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, et al. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384(16):1491–1502. doi: 10.1056/NEJMoa2100433. - DOI - PMC - PubMed
    1. Keske Ş, Tekin S, Sait B, İrkören P, Kapmaz M, Çimen C, et al. Appropriate use of tocilizumab in COVID-19 infection. Int J Infect Dis. 2020;99:338–343. doi: 10.1016/j.ijid.2020.07.036. - DOI - PMC - PubMed
    1. Pawar A, Desai RJ, Solomon DH, Santiago Ortiz AJ, Gale S, Bao M, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Ann Rheum Dis. 2019;78(4):456–464. doi: 10.1136/annrheumdis-2018-214367. - DOI - PubMed

MeSH terms

LinkOut - more resources